|
End-of-day quote
Korea S.E.
2026-08-18
|
5-day change | 1st Jan Change | ||
| 195,500.00 KRW | -2.74% |
|
-7.13% | +13.41% |
| 08-18 | Celltrion's Acquired French Healthcare Firm Becomes Fully Operational | MT |
| 08-04 | Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 31.75B | |||||
| 48.63B | |||||
| 46.3B | - | - | - | - | - |
| 41.97B | |||||
| 39.51B | |||||
| 16.48B |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
